Implementation of optimized supportive care and hospital needs along the management of patients with advanced lung cancer

Lafitte, Claire; Étienne-Mastroïanni, B.; Fournel, Christelle; Natoli, Louise; Foucaut, Aude-Marie; Girard, Nicolas

doi:10.1016/j.lungcan.2018.08.002

Cited by 7 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The outcome of patients with lung cancer metastasis remains dismal. Even if the patients received comprehensive treatment, their prognosis did not improve significantly [8] . So far, however, this patient has survivaled for nearly years.…”

Section: Discussionmentioning

confidence: 91%

Histologic transformation from lung squamous cell carcinoma in primary lesion to small cell lung cancer in metastatic lymph node lesion following lobectomy and adjuvant chemotherapy: a case report

Zhao

Zhang³

et al. 2020

International Journal of Surgery Oncology

View full text Add to dashboard Cite

Introduction: Lung cancer is the leading cause of cancer death worldwide. Histologic transformation from lung squamous cell carcinoma to small cell lung cancer (SCLC) has become more and more, and its treatment is challenging because of unknown pathogenesis. Presentation of Case: A 62-year-old male patient presented with histologic transformation from primary lesion to metastatic recurrence lesion within 3 years following primary lobectomy and adjuvant chemotherapy. The patient had the symptom of cough at the time of initial illness and recurrence. The primary lesion at the root segment of left superior lobe was diagnosed as lung squamous cell carcinoma without gene mutation (including EGFR, ALK, BRAF V600E, etc.), and recurrence lesion at the swollen lymph nodes in mediastinum (4L group) was diagnosed as SCLC. Up to now, the patient was alive for nearly 4 years after first surgery. Discussion: Surgical resection is the main treatment for lung cancer patient in early stage. Lymph node metastasis is a big threat for the patients in early stage. Recently, the research reports focused on the mechanism and cases of histologic transformation of lung cancer have become more and more. In this case, histologic transformation from squamous cell carcinoma in primary focus to SCLC in metastatic lymph node lesion following lobectomy and adjuvant chemotherapy. However, there was no gene mutation. This is a very unusual report. Conclusion:We analyzed a lung cancer patient with histologic transformation from primary focus to lymphatic metastasis by clinical symptoms, radiologic features, laboratory tests, gene detection, histopathologic characteristics, and immunohistochemical testing. It is helpful to understand the pathogenesis of histologic transformation and metastatic progression for optimizing treatment measures to lung cancer.

show abstract

Section: Discussionmentioning

confidence: 91%

Histologic transformation from lung squamous cell carcinoma in primary lesion to small cell lung cancer in metastatic lymph node lesion following lobectomy and adjuvant chemotherapy: a case report

Zhao

Zhang³

et al. 2020

International Journal of Surgery Oncology

View full text Add to dashboard Cite

show abstract

“…31 Ball et al discovered that patients with mesothelioma and lung cancer experienced multifaceted and complex psychological distress. 10 Rodin et al 32 found that patients with Stage IV gastrointestinal and lung cancer had a Karnofsky performance scale of 81.55 and a low level of hopelessness. 32 In our study, as the symptom burden of patients with advanced lung cancer increased and as their Karnofsky performance decreased, their hopelessness level further increased.…”

Section: Discussionmentioning

confidence: 99%

Determine the Symptom Intensities, Performance and Hopelessness Levels of Advanced Lung Cancer Patients for the Palliative Care Approach

Doğan

Özçelik

2022

Am J Hosp Palliat Care

View full text Add to dashboard Cite

This research was conducted descriptively to determine the symptom intensities, performance and hopelessness levels of advanced lung cancer patients for the palliative care approach. The research sample consisted of 130 patients with advanced lung cancer, who were selected from 600 lung cancer populations in thoracic surgery and intensive care, outpatient chemotherapy, oncology in a university hospital in Turkey. Ethics Committee permission and the patients’ written consent was obtained. Study data were collected face to face between January 2020 and July 2020 using the Edmonton Symptom Assessment System, Karnofsky Performance and Beck Hopelessness Scale. The mean age of the patients was 62.68 ± 8.867, 72.3% were males, and 89.2% were not currently working. The most common symptom in the patients was found to be fatigue 5.46 ± 2.12, worsening in general health and well-being 5.69 ± 1.87, loss of appetite 5.40 ± 2.59, and total symptom score 47.17 ± 19.03. Feelings and expectations about the future 1.40 ± 1.66, loss of motivation 3.43 ± 2.41, hope 2.05 ± 1.75, and total score of hopelessness 7.41 ± 6.01. There was a positive correlation between the patients’ hopelessness level and their symptom burden, and a negative correlation was found with Karnofsky performance ( P < .05). A significant difference was found between the patients’ age, months since diagnosis, gender, education and employment status, stage of the disease, presence of metastases and analgesic use, and hopelessness scores ( P < .05). It was determined that the symptom burden of patients with advanced lung cancer increased and as their Karnofsky performance decreased, their hopelessness level further increased. Hopelessness scores are affected by the socio-demographic and disease variables of the patients.

show abstract

“…At the time of diagnosis, patients with lung cancer may be relatively asymptomatic of their disease, however, the evolution of lung cancer is usually marked by symptoms that are likely to significantly impact on their quality of life (Lafitte et al, 2018). Patients with advanced disease face a shortened life expectancy, that can become progressively more symptomatic, highlighting the importance of early recognition and management of physical symptoms (Yount et al, 2012).…”

Section: Rapid Assessment and Management Of Physical And Psychologica...mentioning

confidence: 99%

“…Patients with advanced disease face a shortened life expectancy, that can become progressively more symptomatic, highlighting the importance of early recognition and management of physical symptoms (Yount et al, 2012). One of the potential benefits of independent nurse prescribing for individuals with advanced lung cancer is related to the prompt assessment and management of distressing symptoms such as dyspnoea and pain (Lafitte et al, 2018). Independent nurse prescribers can lawfully prescribe controlled drugs such as morphine sulphate (Griffith and Tengnah, 2011), therefore, contributing to the prompt intervention in the management of symptoms.…”

Section: Rapid Assessment and Management Of Physical And Psychologica...mentioning

confidence: 99%

Role of the clinical nurse specialist as a non-medical prescriber in managing the palliative care needs of individuals with advanced lung cancer

Osborne

Kerr

2021

Int J Palliat Nurs

View full text Add to dashboard Cite

Background: Rapid identification of the palliative care needs of individuals with a diagnosis of advanced lung cancer is crucial to maximise the patient's quality of life by upholding exemplary standards of patient-centred holistic care. The clinical nurse specialist is in an ideal position to contribute to the identification and management of the palliative care needs of individuals with advanced lung cancer through the assessment and timely prescribing of medications to manage distressing symptoms. Aim: This paper reviews and critiques the role of the clinical nurse specialist as an independent non-medical prescriber in the management of palliative symptoms in end-of-life care for patients with advanced lung cancer. Results: Published literature highlights the positive impact the clinical nurse specialist has as a non-medical prescriber in addressing the palliative needs of individuals with lung cancer. However, there are barriers and challenges, and to overcome these, maximising resources and the availability of support is required to ensure the delivery of timely, person-centred care. Conclusion: The clinical nurse specialist as a non-medical prescriber is an evolving role. There are a range of factors that may influence the clinical nurse specialist to confidently and competently undertake this role. These include the perception that there will be an escalation in the workload, concerns about increased accountability and inadequate mentoring for this new role. To incentivise this role, multidisciplinary support is essential in promoting the clinical nurse specialist's confidence for developing this service to individuals with advanced lung cancer.

show abstract

Implementation of optimized supportive care and hospital needs along the management of patients with advanced lung cancer

Cited by 7 publications

References 19 publications

Histologic transformation from lung squamous cell carcinoma in primary lesion to small cell lung cancer in metastatic lymph node lesion following lobectomy and adjuvant chemotherapy: a case report

Histologic transformation from lung squamous cell carcinoma in primary lesion to small cell lung cancer in metastatic lymph node lesion following lobectomy and adjuvant chemotherapy: a case report

Determine the Symptom Intensities, Performance and Hopelessness Levels of Advanced Lung Cancer Patients for the Palliative Care Approach

Role of the clinical nurse specialist as a non-medical prescriber in managing the palliative care needs of individuals with advanced lung cancer

Contact Info

Product

Resources

About